Jazz Pharmaceuticals Q1 2026 Preview: Key Numbers Ahead

Earnings date, time, and what markets will watch

Jazz Pharmaceuticals (NASDAQ: JAZZ) is scheduled to report Q1 2026 results on Tuesday, May 5, after market hours. A conference call is slated for 4:30 PM ET, which is typically when management provides detail on drivers, pipeline updates, and outlook. The setup matters because Jazz has delivered both beats and misses in recent quarters, which can amplify reactions to small deviations versus consensus. Investors will also track whether management commentary aligns with a recent upturn in pharma sector sentiment. Over the last month, pharmaceutical stocks are up about 6% on average, while Jazz shares are up 9.7% over the same period. Heading into the print, the stock is cited around $105 in one data set and near $101 in another, highlighting that the reference points come from different snapshots. Analysts’ price targets also differ by source, with averages of $126.12 and $116.87 both cited alongside a “Moderate Buy” consensus.

Street expectations for Q1 2026

Consensus expectations referenced in the provided material call for Q1 2026 revenue of about $176.631 million and earnings of $1.63 per share. Another estimate snapshot also lists an EPS projection of $1.57 for Q1 2026, underscoring how consensus can vary by provider and timing. The broader expectation is for Jazz’s revenue to rise 8.8% year on year this quarter, improving from flat growth in the comparable quarter last year. Most analysts have reconfirmed their estimates over the last 30 days, which typically signals a “stay the course” stance into the event. That said, the company has missed Wall Street revenue estimates multiple times over the last two years, making the revenue line and product mix especially important. Investors will likely focus on whether the company’s performance this quarter is consistent with its longer-run revenue growth forecast of 7.2% per annum.

How the last quarter shaped expectations

In the prior reported quarter, Jazz posted revenue of $1,200 million, a year-on-year increase reported as 10.1% in one summary and 8.1% in another. That quarter also featured an EPS beat: Jazz reported $1.64 per share versus a consensus estimate of $1.49, a $1.15 outperformance. Revenue of $1,200 million compared with expectations of $1,170 million. Despite the quarterly beat, one summary described it as a slower quarter because full-year revenue guidance missed analysts’ expectations. The reported profitability signals were mixed as well, with a negative net margin of 8.35% alongside a positive return on equity of 6.87%.

Peer read-through: Eli Lilly and Merck set the tone

Some large pharmaceutical peers have already reported Q1 results, offering context for investor sentiment into Jazz’s earnings. Eli Lilly delivered year-on-year revenue growth of 55.5% and beat analyst expectations by 13.7%, with the stock rising 13.2% after results. Merck reported revenue growth of 4.9% and topped estimates by 3%, and the shares were up 1%. While Jazz’s business model and portfolio differ materially from these larger peers, strong peer reactions can lift the broader segment and raise expectations for clean execution. The recent sector move is consistent with the 6% average rise in pharma share prices over the last month.

Stock setup: price targets, market cap, and ownership signals

Ahead of the report, Jazz is described as trading near $101 with a market capitalisation of roughly $12.4 billion. The average analyst price target is cited at $126.12 in one section and $116.87 in another, with the stock price cited around $105 in the same context as the $126.12 target. These differences likely reflect different “last updated” timestamps and data aggregators, rather than a single definitive number. Ownership and trading indicators were also highlighted: institutional ownership is about 89%, and insiders sold approximately 74,015 shares worth about $14.2 million over the past 90 days.

Longer-term growth forecasts and what they imply

The supplied forecasts indicate Jazz is expected to grow earnings and revenue by 31.8% and 7.2% per annum, respectively. EPS is expected to grow by 32.9% per annum, and return on equity is forecast to reach 21.08% in three years. A separate snippet notes: “High Growth Earnings: JAZZ is expected to become profitable in the next 3 years.” The same block also states Jazz’s revenue growth forecast (7.2% per year) is slower than the broader US market’s 11.1% per year and below a 20% “high growth” threshold.

Guidance and full-year context already in play

Jazz has also referenced revenue guidance of $1,200 million to $1,300 million, compared with a consensus revenue estimate of $1,200 million. Separately, the company reported record total revenues of $1,300 million in 2025, up 5% year on year. For investors, the key issue is how Q1 execution and management commentary fit within the existing annual framework, especially given the history of quarterly surprises.

Key numbers at a glance

What to track on the call

Beyond the headline revenue and EPS, investors typically listen for clarity on demand trends and what is driving any gap versus consensus. With Jazz having missed revenue estimates multiple times over the last two years, the composition of revenue can matter as much as the total. Updates tied to regulatory and pipeline timelines were also referenced in the supplied material, including an expectation to complete an sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA. Any reiteration or change in these timelines can influence expectations, especially when the stock is already up 9.7% over the past month.

Conclusion

Jazz Pharmaceuticals heads into its May 5 Q1 2026 earnings report with consensus pointing to $176.631 million in revenue and $1.63 EPS, after a prior-quarter revenue and EPS beat. With pharma peers posting solid quarters and the sector trending higher, the focus will be on whether Jazz delivers in line with estimates and maintains alignment with its cited $1,200 million to $1,300 million revenue guidance range. The next clear checkpoint is the post-close release followed by the 4:30 PM ET conference call.